Boston Scientific pauses AVANT GUARD trial over unexpected observations in drug-naive patients.

Boston Scientific has temporarily paused enrollment in its AVANT GUARD trial, which assesses the safety and effectiveness of its Farapulse Pulsed Field Ablation System for treating persistent atrial fibrillation. This decision follows unexpected observations in drug-naive patients, a group not previously studied. Despite this setback, the company reported strong third-quarter sales of $4.21 billion, driven by a significant increase in electrophysiology sales.